Maryland State Health Secretary to Join Johns Hopkins Bloomberg School of Public Health
Joshua M. Sharfstein named Associate Dean for Public Health Practice and Training
Article ID: 621327
Released: 30-Jul-2014 10:00 AM EDT
Source Newsroom: Johns Hopkins Bloomberg School of Public Health
Newswise — Joshua M. Sharfstein, the Secretary of the Maryland Department of Health and Mental Hygiene (DHMH), will join the full-time faculty of the Johns Hopkins Bloomberg School of Public Health as the new Associate Dean for Public Health Practice and Training, effective Jan. 1, 2015. Sharfstein will also hold a faculty appointment in the Department of Health Policy and Management.
As secretary of DHMH, Sharfstein has led efforts to modernize Maryland’s all-payer system for hospital payment. He also serves as a member of the editorial board at the Journal of the American Medical Association (JAMA). Prior to joining the state, he was Principal Deputy Commissioner of the U.S. Food and Drug Administration and, before that, Baltimore City’s Commissioner of Health. He began working on health and social policy matters as an advisor to longtime California Congressman Henry A. Waxman, where he was responsible for projects related to public health.
“Josh Sharfstein has had a distinguished career in public health practice and policy and we are delighted that he is joining the faculty of the Bloomberg School,” says Dean Michael J. Klag. “Josh will bring a wealth of experience and insights that will strengthen the practice, teaching, and research opportunities available to our faculty and students.”
“I look forward to joining a team of scholars that is making the world healthier, safer, and more sustainable,” Sharfstein says. “I will stay involved in my city of Baltimore and my state of Maryland, as I engage with national and global health policy challenges and help train future public health leaders.”
As associate dean, Sharfstein succeeds Thomas Burke, who has provided leadership in public health practice, created a number of innovative programs, and strengthened ties to the practice community since assuming the position in September of 2008. Burke is President Obama’s nominee to lead the Environmental Protection Agency’s Office of Research and Development. Dr. Burke will remain in his current role as Associate Dean until Dr. Sharfstein joins the School and, until his confirmation by the Senate, as director of the School’s Risk Sciences and Public Policy Institute and a professor with joint appointments in the departments of Health Policy and Management and Environmental Health Sciences.
A Maryland native, Sharfstein is a graduate of Harvard College and Medical School and is trained in pediatrics. During his training, Sharfstein worked with the Massachusetts Department of Public Health and the World Health Organization. He was a Contributing Editor at Public Health Reports and serves on the Board on Population Health and Public Health Practice of the Institute of Medicine. He continues to see pediatric outpatients.
“As a pediatrician and as a public servant, Josh Sharfstein has been committed to children, families, and improving people's lives,” says Governor Martin O’Malley. “As the Secretary of Health and Mental Hygiene, he's led the way as we have invested in public health and prevention, aligned the health care system to the vision of better health at lower cost, and expanded health care coverage to hundreds of thousands of Marylanders. As a Marylander, I'm thrilled that he's going to Johns Hopkins.”
As a volunteer during medical school with the FDA, Sharfstein wrote and edited portions of the agency's legal argument to regulate tobacco as an addictive drug. As a policy adviser to Congressman Waxman, he helped to write legislation requiring the FDA to regulate colored contact lenses not as cosmetics but medical devices.
As city health commissioner, Sharfstein led a campaign warning parents not to use over-the-counter cough and cold medications after the deaths of four city children under the age of 4. He later was the lead author of a petition to the FDA that led manufacturers to remove cold-and-cough medications for children under age 4 from the market.
“We already know Josh from his lectures at our school, his mentorship of our students and our productive collaborations and we look forward to his full-time presence and impact at the school,” Klag says. “We know that he will build on the very strong foundation of practice and policy activities already here to create new synergies and increase the impact of our work.”
# # #